EHA 2015: Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression or death

EHA 2015: Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression or death

EMJ

4 years
1,068 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
ELOQUENT-2, a phase 3, randomised, open-label study of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory multiple myeloma, met its primary endpoints of progression-free survival and overall response rate. The two-year progression-free survival rate was 41% in the elotuzumab group versus 27% in the control group. The overall response rate in the elotuzumab group was 79% versus 66% in the control group.

Presented by Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, at the 20th Congress of the European Hematology Association (EHA)



European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay